Results 151 to 160 of about 8,866 (177)

Signaling pathways in systemic lupus erythematosus and therapeutic implications. [PDF]

Front Immunol
Balogh L, Kovács VG, Nagy G, Németh T.
europepmc   +1 more source

A new era in chronic spontaneous urticaria: FDA approval of the oral BTK inhibitor remibrutinib. [PDF]

Ann Med Surg (Lond)
Jan M, Qazi K, Noor A, Naveed M, Khalid M, Waafira A.   +5 more
europepmc   +1 more source

Bruton's tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy. [PDF]

Ann Med Surg (Lond)
Hujjat SFZ, Chandani HK, Khan MS, Chandani DK, Mahmoud A.   +4 more
europepmc   +1 more source

Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center. [PDF]

Adv Hematol
Lin KH, Huynh L, Yang X, Zanardo E, Liborski D, McDonough MM, Farooqui MZH, De Nigris E, Gandra SR, Duh MS, Brown JR, Davids MS.   +11 more
europepmc   +1 more source

Epidemiology of chronic lymphocytic leukaemia in Germany: A retrospective analysis of administrative claims data. [PDF]

Ann Hematol
Maqhuzu PN, Bocuk D, Boelz S, Hosseini SK, Leeb C, Renevey F, Mevius A, Greth K, Christofyllakis K.   +8 more
europepmc   +1 more source

Evaluation of Cardiotoxicity in Lymphoproliferative Patients Treated With Anthracycline and Bruton's Tyrosine Kinase Inhibitor-Based Regimens. [PDF]

Cureus
Bonsu A.
europepmc   +1 more source

Comparison of One-Year Adverse Events Between First- and Second-Generation Bruton's Tyrosine Kinase Inhibitors: A Retrospective Study. [PDF]

Cureus
Ito A, Ito K, Iriyama C, Goto N, Inamoto Y, Okamoto M, Hirose Y, Morisaku M, Yamada S, Hayakawa N, Tomita A.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

Ca-A Cancer Journal for Clinicians, 2022
Sharon Elad, Noam Yarom, Yehuda Zadik
exaly